Jennison Associates Portfolio holdings
Jennison Associates, founded in 1969 and headquartered in New York City, is a global investment management firm managing over $194 billion in assets as of late 2024, specializing in active equity and fixed-income strategies. A subsidiary of PGIM, the asset management arm of Prudential Financial, Jennison serves a diverse client base—including institutions, sub-advisory clients, public plans, endowments, and corporations—with a focus on fundamental research, bottom-up portfolio construction, and high-conviction investing. Known for its equity expertise across styles, geographies, and market capitalizations, as well as investment-grade fixed-income offerings, the firm employs seasoned portfolio managers averaging 29 years of industry experience and 16 years with Jennison. With additional offices in Boston and a culture emphasizing intellectual rigor and long-term client outcomes, Jennison has built a reputation for excellence and stability in the investment management industry.
Top Buys
| 1 |
Broadcom
AVGO
|
+$831M |
| 2 |
Nike
NKE
|
+$780M |
| 3 |
ATVI
Activision Blizzard Inc.
ATVI
|
+$608M |
| 4 |
Texas Instruments
TXN
|
+$512M |
| 5 |
AGN
Allergan plc
AGN
|
+$389M |
Top Sells
| 1 |
Starbucks
SBUX
|
+$1.1B |
| 2 |
Qualcomm
QCOM
|
+$665M |
| 3 |
TJX Companies
TJX
|
+$618M |
| 4 |
Regeneron Pharmaceuticals
REGN
|
+$448M |
| 5 |
NVIDIA
NVDA
|
+$441M |
Sector Composition
| 1 | Technology | 20.36% |
| 2 | Consumer Discretionary | 17.4% |
| 3 | Healthcare | 13.53% |
| 4 | Communication Services | 13.11% |
| 5 | Financials | 10.46% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Shares Change % | Capital Flow | |
|---|---|---|---|---|---|---|
|
TVRD
501
Tvardi Therapeutics, Inc. Common Stock
TVRD
$278M
| $5.52M | 0.01% |
+8,333
| New | +$5.52M |
|
|
TRHC
502
DELISTED
Tabula Rasa HealthCare, Inc. Common Stock
TRHC
| $5.46M | 0.01% |
405,194
| – | – |
|
|
STKL
503
SunOpta
STKL
$765M
| $5.39M | 0.01% |
774,779
-1,815,104
| -70% | -$12.6M |
|
504
Surgery Partners
SGRY
$2.83B
| $5.2M | 0.01% |
266,647
-750,563
| -74% | -$14.6M |
|
|
PETX
505
DELISTED
Aratana Therapeutics, Inc.
PETX
| $5.17M | 0.01% |
975,369
-171,558
| -15% | -$909K |
|
|
BOLD
506
DELISTED
Audentes Therapeutics, Inc
BOLD
| $5.11M | 0.01% |
299,656
| – | – |
|
507
REV Group
REVG
$3.03B
| $4.78M | 0.01% |
+173,351
| New | +$4.78M |
|
|
RARX
508
DELISTED
Ra Pharmaceuticals, Inc. Common Stock
RARX
| $4.31M | ﹤0.01% |
202,500
| – | – |
|
509
Norfolk Southern
NSC
$61.8B
| $4.31M | ﹤0.01% |
38,476
-47,976
| -55% | -$5.37M |
|
|
CACB
510
DELISTED
Cascade Bancorp
CACB
| $4.29M | ﹤0.01% |
556,240
-95,148
| -15% | -$734K |
|
511
Tempest Therapeutics
TPST
$48.2M
| $4.08M | ﹤0.01% |
747
| – | – |
|
512
Exxon Mobil
XOM
$472B
| $3.69M | ﹤0.01% |
45,016
-69,213
| -61% | -$5.68M |
|
513
iRhythm Technologies
IRTC
$5.99B
| $3.63M | ﹤0.01% |
96,571
-108,723
| -53% | -$4.09M |
|
514
MacroGenics
MGNX
$111M
| $3.51M | ﹤0.01% |
188,908
| – | – |
|
515
Berkshire Hathaway Class B
BRK.B
$1.06T
| $3.38M | ﹤0.01% |
20,305
-31,791
| -61% | -$5.3M |
|
516
Johnson & Johnson
JNJ
$426B
| $3.33M | ﹤0.01% |
26,745
-46,887
| -64% | -$5.84M |
|
517
SPDR S&P Metals & Mining ETF
XME
$2.33B
| $3.3M | ﹤0.01% |
108,322
+1,831
| +2% | +$55.7K |
|
|
XL
518
DELISTED
XL Group Ltd.
XL
| $3.19M | ﹤0.01% |
79,906
-13,467
| -14% | -$537K |
|
519
Emerson Electric
EMR
$74.7B
| $3.01M | ﹤0.01% |
50,207
+39,797
| +382% | +$2.38M |
|
520
Elevance Health
ELV
$69.4B
| $2.91M | ﹤0.01% |
17,572
-875
| -5% | -$145K |
|
521
Omega Healthcare
OHI
$12.8B
| $2.86M | ﹤0.01% |
86,753
+53,991
| +165% | +$1.78M |
|
522
Walt Disney
DIS
$211B
| $2.55M | ﹤0.01% |
22,496
-249,901
| -92% | -$28.3M |
|
|
FENX
523
DELISTED
Fenix Parts, Inc.
FENX
| $2.54M | ﹤0.01% |
1,638,189
-200,163
| -11% | -$310K |
|
|
NAK
524
Northern Dynasty Minerals
NAK
$450M
| $2.52M | ﹤0.01% |
1,763,422
| – | – |
|
525
Citizens Financial Group
CFG
$22.3B
| $2.46M | ﹤0.01% |
71,328
-29,855
| -30% | -$1.03M |
|